These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib]. Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM. Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858 [Abstract] [Full Text] [Related]
3. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J. Oncology; 2005; 69(4):326-32. PubMed ID: 16293972 [Abstract] [Full Text] [Related]
4. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662 [Abstract] [Full Text] [Related]
5. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. J Clin Oncol; 2007 May 01; 25(13):1753-9. PubMed ID: 17470865 [Abstract] [Full Text] [Related]
10. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor]. Delgado Bolton RC, Ortega Candil A, Pérez Castejón MJ, Garcerant M, Cabrera Martín MN, Lapeña Gutiérrez L, Carreras Delgado JL. Rev Esp Med Nucl; 2008 Apr 27; 27(2):112-7. PubMed ID: 18367049 [Abstract] [Full Text] [Related]
11. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, Schnyder P, Luthi F, von Schulthess GK, Leyvraz S. Eur J Nucl Med Mol Imaging; 2005 Feb 27; 32(2):153-62. PubMed ID: 15690223 [Abstract] [Full Text] [Related]
12. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H. Anticancer Res; 2005 Feb 27; 25(6C):4591-4. PubMed ID: 16334147 [Abstract] [Full Text] [Related]
13. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT. Schmidt S, Dunet V, Koehli M, Montemurro M, Meuli R, Prior JO. Acta Radiol; 2013 Oct 27; 54(8):837-42. PubMed ID: 23761549 [Abstract] [Full Text] [Related]
14. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA. AJR Am J Roentgenol; 2004 Dec 27; 183(6):1619-28. PubMed ID: 15547201 [Abstract] [Full Text] [Related]
15. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. Treglia G, Mirk P, Stefanelli A, Rufini V, Giordano A, Bonomo L. Clin Imaging; 2012 Dec 27; 36(3):167-75. PubMed ID: 22542374 [Abstract] [Full Text] [Related]
16. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Jager PL, Gietema JA, van der Graaf WT. Nucl Med Commun; 2004 May 27; 25(5):433-8. PubMed ID: 15100500 [Abstract] [Full Text] [Related]
17. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA. J Nucl Med; 2012 Apr 27; 53(4):567-74. PubMed ID: 22381410 [Abstract] [Full Text] [Related]
18. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, Bockisch A, Debatin JF, Freudenberg LS. J Nucl Med; 2004 Mar 27; 45(3):357-65. PubMed ID: 15001674 [Abstract] [Full Text] [Related]
19. Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T. Acta Oncol; 2014 Jan 27; 53(1):143-8. PubMed ID: 23710697 [No Abstract] [Full Text] [Related]
20. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, Nishitani H. J Med Invest; 2010 Aug 27; 57(3-4):270-4. PubMed ID: 20847527 [Abstract] [Full Text] [Related] Page: [Next] [New Search]